ePT--the Electronic Newsletter of Pharmaceutical Technology
University of Calgary biochemists used computer simulation in a new toxicity study to predict how "buckyballs," carbon-60 soccer ball-shaped nanomolecules, could damage animal cells.
Calgary, Canada (May 26)-University of Calgary biochemists used computer simulation in a new toxicity study to predict how “buckyballs,” carbon-60 soccer ball-shaped nanomolecules, could damage animal cells. Results could explain how these molecules could be toxic to humans and animals.
The team modeled the interaction between the molecules and the cell membranes using a high-powered computing system called “WestGrid,” which is a partnership among 14 Canadian institutions. Cell behavior simulations showed how the buckyballs are able to dissolve in cell membranes, pass into cells, and reform particles on the other side where they can damage cells.
“Buckyballs are already being made on a commercial scale for use in coatings and materials, but we have not determined their toxicity,” said Peter Tielman, senior scholar at the Alberta Heritage Foundation for Medical Research, in a press release. “There are studies showing that they can cross the blood-brain barrier and alter cell functions, which raises a lot of questions about their toxicity and what impact they may have if released into the environment.”
The spherical carbon-60 molecules were discovered in 1985 and named Buckminsterfullerenes (after Richard Buckminster Fuller, the inventor of the geodesic dome). Known as “buckyballs,” these molecules can produce hollow fibers known as carbon nanotubes. Both buckyballs and carbon nanotubes are of interest in nanotechnology because of their strength and heat resistance, and both have been of interest in drug delivery applications. Research has focused on their toxicity because fullerenes have been shown to cause brain damage in fish and inhaling carbon nanotubes have been shown to cause lung damage.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.